A subset of patients with systemic lupus erythematosus has autoantibodies to acidic phospholipids. Since lipids are poor immunogens, the mechanism responsible for the induction of these antibodies is unclear. Immunization of a normal rabbit and normal mice with purified human g62-glycoprotein I (apolipoprotein H) resulted in the production of high levels of two non-cross-reactive antibody populations, anti-apolipoprotein H, and antiphospholipid. The antiphospholipid antibodies had binding specificities indistinguishable from autoantibodies obtained from human and murine lupus. These findings suggest a novel mechanism for the induction ofantiphospholipid autoantibodies. (J. Clin. Invest. 1992. 90:1105-1109
Introduction
Autoantibodies (aPL)1 directed against phospholipids (PL) such as cardiolipin occur in systemic lupus erythematosus (SLE) and related disorders (1) (2) (3) (4) (5) . These autoantibodies are associated with serious clinical complications, viz., thrombosis and intrauterine fetal death secondary to placental infarction (6) (7) (8) (9) . In spite ofthe relatively high frequency with which these antibodies are detected, the mechanism(s) responsible for their induction remains an enigma. Lipids are poor immunogens and usually require a protein or carbohydrate carrier to stimulate antibody production (10, 11 ) . As in the case of anti-DNA antibodies ( 12, 13) , aPL directed against acidic PL cannot be induced simply by immunization with phospholipids in Freund's adjuvant. Some aPL have been induced experimentally by complex methods including immunization with cardiolipin and heterologous serum ( 14) , frequent intravenous injection of lipid coupled to methylated bovine albumin ( 15 ) , intraperitoneal injection of lipid coupled to monoclonal aPL-coated Staphylococcus aureus ( 16) , and intrasplenic immunization with Salmonella minnesota coated with lipid ( 17) . aPL have also been induced in experimental animals by immunization with liposomes containing various lipids (dipalmitoyl phosphatidylcholine, cholesterol, dicetyl phosphate, and lipid A) ( 18, 19) . Mice immunized with phosphatidylethanolamine in hexagonal II phase have been shown to produce antiphosphatidylethanolamine antibodies that cross-react with cardiolipin (20) . The relevance of these findings to autoantibody production in humans with SLE is uncertain. In this report, we describe production of high levels ofantiphospholipid antibodies by immunization with a protein antigen. This protein is 12-glycoprotein I (apolipoprotein H, apo H) a 50-kD molecular mass plasma component, which binds to acidic phospholipids (21 ) and is believed to have a regulatory effect on coagulation (22, 23) . Since this protein has been shown to enhance the binding of aPL to PL, apo H has been termed the aPL cofactor (24, 25) .
Methods

Purification and characterization ofapo H
Human, bovine, and mouse apo H were purified by perchloric acid treatment of serum followed by ion-exchange chromatography on QAE-Sephadex A-50 (Pharmacia LKB Biotechnology Inc., Pitscataway, NJ) (26) . Fractions were tested for aPL cofactor activity by ELISA (27) . The preparation was analyzed for protein by SDS-PAGE and for lipids by chloroform methanol extraction followed by high performance thin layer chromatography (28 (Fig. 3) . Immunization of normal mice (group A) with a second preparation of human apo H also induced the production of anti-apo H and aPL antibodies (Fig. 4) . In contrast, when normal mice (group B) were immunized with HSA into which cardiolipin was intentionally mixed, the mice produced high . The sera were then tested for aPL activity (Fig. 2  A) or anti-apo H activity (Fig. 2 B) by ELISA. The results are expressed as percent inhibition. ., PL; o, apo H. (Fig. 4) . Similarly, when cardiolipin was mixed with apo H and injected into three NIH/Swiss mice using the identical immunization protocol, the immunized mice produced similar levels ofanti-apo H and aPL to mice immunized with apo H alone (not shown). Compared to spontaneous aPL in MRL/lpr mice (29) , apo H-induced murine aPL were of higher levels (Fig. 4) .
As in the case of aPL in autoimmune diseases ( 30, 31), both rabbit and mouse apo H-induced aPL bound to other acidic phospholipids such as phosphatidylserine but did not bind to neutral phospholipids (phosphatidylcholine) (not shown). Similarly, the apo H-induced aPL demonstrated enhanced binding to phospholipids when apo H was added to the ELISA wells, suggesting an antibody preference for an apo Hphospholipid complex.
To determine whether autologous apo H could induce aPL, three groups (groups C-E) of NIH/Swiss mice (three mice per group) were immunized with human, bovine, or mouse apo H (50 ,g per injection) using the immunization protocol described above. Human, bovine, and mouse apo H preparations were virtually identical on SDS-PAGE and produced similar cofactor activity in the aPL ELISA. After two booster injections, only the sera of mice immunized with heterologous apo H (human and bovine) demonstrated aPL activity, while mice immunized with autologous apo H had no aPL activity (OD 0.793±0.396, 0.985+0.425, vs. 0.174±0.015, respectively).
Finally, to determine whether phospholipids present in mycobacteria in CFA were necessary for the induction of aPL, three groups of NIH/ Swiss mice (three mice per group) were immunized with purified human apo H (50 ,ug per injection) using three different adjuvants: incomplete Freund's adjuvant (Difco Laboratories, Detroit, MI) (32) containing only mineral oil and emulsifier (33) (group F); Super Carrier-alum (Pierce Chemical Co., Rockford, IL) containing cationized BSA (34) , and aluminum hydroxide (group G); and CFA (Difco Laboratories) (group H). In all cases, the same adjuvant was used for the initial immunization and for boosting (except for group H which was boosted with incomplete Freund's adjuvant). All other conditions (dose, route, and timing of immunization) were identical to those described for groups A-E. Results of immunization with human apo H in different adjuvants are shown in Table I . Both groups F and G (immunized with phospholipid-free adjuvants) produced high levels of IgM and IgG anti-apo H as well antiphospholipid antibodies comparable to group H which was immunized with phospholipid containing adjuvant. Sera from age-and sexmatched nonimmunized NIH/ Swiss mice were used as controls. The specificity of aPL induced by these adjuvants was confirmed by inhibition with PL micelles (not shown).
Discussion
Immunization with exogenous apo H appears to be a potent method for inducing aPL antibodies. Several mechanisms could explain the induction ofaPL in these experiments. Trace contamination ofapo H with human PL is an unlikely explanation since PL were not detected in the immunogen and addition of PL to an irrelevant foreign protein (HSA) failed to induce aPL under identical conditions. Although mycobac- (Fig. 4) argue against this possibility. We therefore propose that aPL autoantibodies are induced by the binding ofapo H to endogenous PL in vivo. Since aPL are relatively low affinity antibodies (35) and because antibody binding to PL is enhanced in the presence of apo H, a similar mechanism, viz., PL-protein interaction, may explain aPL production in SLE. Since SLE antibodies do not appear to bind directly to human apo H (24), another PL binding protein may be the key immunogen in the phospholipid syndrome in SLE. Identification of this protein may explain both the induction of aPL and may provide a clue to the pathogenesis ofthe associated thrombotic disorder. Furthermore, since we have demonstrated a requirement for foreign apo H in the induction of aPL, immunization by foreign PL-binding proteins may explain the production of aPL in infectious diseases (36, 37) .
Autoantibodies cannot be readily induced by immunization with self antigens. Even in autoimmune-prone strains of mice, immunization with nucleic acid ( 13) or ribonucleoprotein self antigens (38) fails to break tolerance. Autoantibodies have been induced experimentally by other strategies. Immunization with foreign or modified selfantigens induces antibodies that cross-react with self antigens (38) (39) (40) (41) (42) . Antiidiotypic antibodies that bind to self cell surface receptors can be produced by immunization with antibodies (idiotypes) directed against the receptor ligand (43-45). The experiments described in the present report indicate that autoantibodies can be generated by a third mechanism, viz., immunization with a foreign autoantigen-binding protein. This mechanism may have relevance to the induction of autoantibodies to antigens other than PL.
